Inhibition of cholesterol absorption
Lowering LDL levels will lower the risk of CHD. Although statins have been shown to be very effective, a lot of patients still do not reach the goals.
The introduction of the cholesterol absorption inhibitor, ezetimibe, offers an alternative to statin monotherapy. Combining ezetimibe with a statin augments the latter's LDL-lowering efficacy by an additional 15-20% and theoretically should achieve a reduction in CHD risk of similar magnitude, additional to that from statin alone. The effects of ezetimibe on cardiovascular disease remain to be determined but it is an effective adjunct to statins for lowering LDL-cholesterol in hypercholesterolaemic patients who are intolerant of, or refractory to, statins.
Questions to be addressed in this PACE expert opinion are:
- Lowering LDL levels: What is the need for further lowering LDL levels?
- Lowering LDL levels: Does the way LDL is reduced effect CAD risk?
- The ENHANCE trial: What is the background of this trial, and how can the results be explained?
View the expert opinion interview with dr. Hovingh
About the speaker
Dr. Kees Hovingh
Dr. Hovingh works at the Department of Vascular Medicine at the AMC, led by Professor John Kastelein. He will almost finish the training for vascular medicine internist and combines this with one day per week research at the Department of Vascular Medicine.
During his PhD research he worked on research projects focused on unravelling the molecular basis of HDL abnormalities. He particularly focused on the biochemical and vascular consequences of mutations in important HDL genes.
His current research is still focused on lipid lowering and HDL cholesterol.
View teaching slides